Leiden collaboration enhances drug discovery for membrane proteins


A joint effort between Leiden University’s Professor Ubbink’s lab and ZoBio’s Assay Development and Screening team has advanced fragment-based drug discovery targeting membrane proteins. Supported by a Dutch Research Council (NWO) AES grant, the project utilized protein-lipid nanodiscs to study how lipid composition affects small molecule interactions with the membrane enzyme CYP3A4.

Findings revealed that lipid types significantly influence off-target binding, underscoring the importance of lipid selection in drug screening. This research, published in Chemical Biology and Drug Design, offers valuable insights for developing therapeutics targeting complex membrane proteins

Read more here


  • SpectaCell raises €6 million to accelerate drug development

    For the Leiden Bio Science Park, it is great to see SpectaCell connecting its technology with the biotech ecosystem here in Leiden. SpectaCell will combine its technology development and cell analysis in Ghent with further validation and application within the…

  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…